|
Colorectal Carcinoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Review of colorectal carcinomas with known KRAS and NRAS genotype revealed that none of 62 wild-type tumors or 47 mutants other than Q61R were SP174 positive.
|
28353383 |
2017 |
|
Medullary carcinoma of thyroid
|
|
0.710 |
GeneticVariation
|
BEFREE |
Of the seven RET wild-type MTCs, four cases (57.1 %) harbored a RAS mutation: three in HRAS (all Q61R) and one in KRAS (G12R).
|
24828033 |
2014 |
|
Medullary carcinoma of thyroid
|
|
0.710 |
GeneticVariation
|
CLINVAR |
|
|
|
|
Colorectal Carcinoma
|
|
0.710 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Colorectal Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
|
Noonan Syndrome
|
|
0.700 |
CausalMutation
|
CLINVAR |
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
|
20526288 |
2010 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |